S&P 500 Futures
(-0.21%) 5 136.25 points
Dow Jones Futures
(-0.15%) 38 503 points
Nasdaq Futures
(-0.21%) 17 868 points
Oil
(0.40%) $82.96
Gas
(2.41%) $2.08
Gold
(-1.43%) $2 323.90
Silver
(-2.87%) $26.87
Platinum
(-1.56%) $946.50
USD/EUR
(-0.02%) $0.932
USD/NOK
(0.33%) $11.02
USD/GBP
(0.12%) $0.797
USD/RUB
(0.06%) $93.36

Aktualne aktualizacje dla Fortress Biotech Inc. [FBIOP]

Giełda: NASDAQ Sektor: Healthcare Branża: Biotechnology
Ostatnio aktualizowano29 bal. 2024 @ 23:00

6.39% $ 14.81

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 23:00):
Profile picture for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne...

Stats
Dzisiejszy wolumen 13 521.00
Średni wolumen 12 441.00
Kapitalizacja rynkowa 32.80M
EPS $-0.000220 ( 2023-06-29 )
Last Dividend $0.195 ( 2023-12-14 )
Next Dividend $0 ( N/A )
P/E -17.16
ATR14 $0.250 (1.69%)
Insider Trading
Date Person Action Amount type
2024-01-05 Rosenwald Lindsay A Md Buy 50 000 COMMON STOCK, PAR VALUE $0.001
2024-01-01 Lu Lucy Buy 3 333 COMMON STOCK, PAR VALUE $0.001
2024-01-01 Lorenz Kevin Buy 3 333 COMMON STOCK, PAR VALUE $0.001
2024-01-01 Lobell J Jay Buy 6 666 COMMON STOCK, PAR VALUE $0.001
2024-01-01 Klein Dov Buy 6 666 COMMON STOCK, PAR VALUE $0.001
INSIDER POWER
100.00
Last 51 transactions
Buy: 13 110 352 | Sell: 133 334

Fortress Biotech Inc. Korelacja

10 Najbardziej pozytywne korelacje
SVFD0.82
RMRM0.813
TSVT0.806
PHUN0.805
NURO0.803
TANH0.803
10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Fortress Biotech Inc. Finanse

Annual 2023
Przychody: $84.51M
Zysk brutto: $55.62M (65.82 %)
EPS: $-7.48
FY 2023
Przychody: $84.51M
Zysk brutto: $55.62M (65.82 %)
EPS: $-7.48
FY 2022
Przychody: $75.74M
Zysk brutto: $44.97M (59.37 %)
EPS: $-36.10
FY 2021
Przychody: $68.79M
Zysk brutto: $36.71M (53.36 %)
EPS: $-0.980

Financial Reports:

No articles found.

Fortress Biotech Inc. Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.390
(N/A)
$0.586
(N/A)
$0.586
(N/A)
$0.586
(N/A)
$0.586
(N/A)
$0.586
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Fortress Biotech Inc. Dividend Information - Dividend King

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 5.00 - Potential for dividend initiation, but uncertain (0.00%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.586 2018-03-14
Last Dividend $0.195 2023-12-14
Next Dividend $0 N/A
Payout Date 2023-12-31
Next Payout Date N/A
# dividends 51 --
Total Paid Out $13.86 --
Avg. Dividend % Per Year 7.56% --
Score 5.87 --
Div. Sustainability Score 0
Div.Growth Potential Score 5.00
Div. Directional Score 1.121 --
Next Divdend (Est)
(2024-07-01)
$0.205 Estimate 40.00 %
Dividend Stability
0.80 Very Good
Dividend Score
5.87
Pay Frequency
Monthly
Yearly Payout
Year Amount Yield
2018 $2.34 10.60%
2019 $2.34 14.50%
2020 $2.34 11.40%
2021 $2.34 12.10%
2022 $2.15 8.20%
2023 $2.34 13.30%
2024 $0 0.00%

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
OXSQ Dividend Diamond 2023-12-14 Monthly 21 9.10% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-0.7241.500-10.00-10.00[0 - 0.5]
returnOnAssetsTTM-0.3651.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-2.561.500-10.00-10.00[0.1 - 1]
payoutRatioTTM-0.143-1.000-1.4321.432[0 - 1]
currentRatioTTM1.3780.8008.116.49[1 - 3]
quickRatioTTM1.1340.8008.036.43[0.8 - 2.5]
cashRatioTTM0.9531.5005.828.72[0.2 - 2]
debtRatioTTM0.420-1.5003.01-4.51[0 - 0.6]
interestCoverageTTM-11.921.000-5.53-5.53[3 - 30]
operatingCashFlowPerShareTTM-8.502.00-2.83-5.66[0 - 30]
freeCashFlowPerShareTTM-8.572.00-4.28-8.57[0 - 20]
debtEquityRatioTTM3.12-1.50010.00-10.00[0 - 2.5]
grossProfitMarginTTM0.6801.0001.9991.999[0.2 - 0.8]
operatingProfitMarginTTM-1.6811.000-10.00-10.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-1.8241.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM0.5040.8009.977.98[0.5 - 2]
Total Score-2.76

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-0.4241.000-0.1440[1 - 100]
returnOnEquityTTM-2.562.50-10.00-10.00[0.1 - 1.5]
freeCashFlowPerShareTTM-8.572.00-2.86-8.57[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-8.502.00-2.83-5.66[0 - 30]
payoutRatioTTM-0.1431.500-1.4321.432[0 - 1]
pegRatioTTM01.500-3.330[0.5 - 2]
operatingCashFlowSalesRatioTTM-1.5171.000-10.000[0.1 - 0.5]
Total Score-3.87

Fortress Biotech Inc.

Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.

O Sygnały na żywo

Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.

Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej